The FDA expanded the approval of the direct-acting antiviral (DAA) glecaprevir/pibrentasvir (Mavyret), making it the first ...

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for a label expansion for MAVYRET ...

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus: North Chicago Saturday, June 14, 2025, 11:00 Hrs [IST] AbbVie announced tha ...

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

Learn about 5 liver infections that can hide in your body for decades without symptoms. Discover warning signs and prevention ...

The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc’s (NYSE:ABBV) Mavyret ...

FDA approved a label expansion for Mavyret for the treatment of acute hepatitis C virus, according to a press release from ...

The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in ...

Asian Americans, who make up 7% of the U.S. population, account for more than half of all chronic hepatitis B cases. Roughly ...